A股异动 | 美瑞新材(300848.SZ)大涨逾15% 2020年净利升22.39% 拟10转10派2元
格隆汇3月16日丨美瑞新材(300848.SZ)盘初一度涨停,现报57.4元,涨幅收窄至15.38%,暂成交1.51亿元,总市值38.27亿元。美瑞新材15日披露2020年度报告,报告期内,公司实现营业收入7.57亿元,同比增长16.71%;归属于上市公司股东的净利润1.02亿元,同比增长22.39%;基本每股收益1.79元,年报推10转10派2元(含税)。2020年,公司二期项目完成了自动包装,自动码垛,自动入库的设备调试,将其与ERP、WMS、系统集成,大幅度提升了公司生产效率,效率大幅提升。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.